US Edition
RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit
- A class action lawsuit has been initiated to represent investors who purchased shares of Rocket Pharmaceuticals, Inc. from late February through late May 2025, alleging violations related to securities fraud.
- The lawsuit arises after the company announced a clinical hold by the FDA on its Phase 2 RP-A501 trial on May 27, 2025, following serious adverse events including a patient death.
- The complaint claims defendants gave overwhelmingly positive but materially false statements and concealed adverse facts about RP-A501’s safety and trial protocol, causing shares to crash over 60% on May 27, 2025.
- Investors may seek compensation without out-of-pocket fees by moving to serve as lead plaintiff by August 11, 2025, with Rosen Law Firm experienced in recovering hundreds of millions for investors.
- The case highlights the risks in clinical drug development and could result in significant recovery for affected investors if the claims of misrepresentation and concealment prove true.
Insights by Ground AI
Does this summary seem wrong?
61 Articles
61 Articles
All
Left
5
Center
23
Right
3
RECKITT BENCKISER SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Reckitt Benckiser Group PLC
NEW ORLEANS, June 13, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 4, 2025 to file lead plaintiff applications in a securities class action lawsuit against Reckitt Benckiser Group PLC ("Reckitt" or…
PR NewswireReposted by 
CNHI News
CNHI NewsRCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit
/PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between...
·United States
Read Full Article
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049...
Coverage Details
Total News Sources61
Leaning Left5Leaning Right3Center23Last UpdatedBias Distribution74% Center
Bias Distribution
- 74% of the sources are Center
74% Center
L 16%
C 74%
Factuality
To view factuality data please Upgrade to Premium
